That is my thought Pine. Govt's desperately want an alz treatment to save them money. Yes, save. Because current institutional care costs a fortune. that is also why they are willing to fund trials in Australia.
So both in Australia and the US, they have cleared the regulatory path for accelerated approval. It is a priority for both govts.
When you have a product like 273 that has virtually no side effects, is incredibly safe, and is the only drug ever to show patients improving from the disease, it is a slam dunk for accelerated approval if patients show improvement in the P3. I think we go six months, the data gets submitted and accelerated approval is granted. Which means we could be having sales this year.
Just get the darn trial started already so we can begin the countdown, T minus six month and counting.
News 
Market Data 
Discover 
